Anti-RNA virus activity of polyoxometalates.
Identifieur interne : 003F83 ( Main/Exploration ); précédent : 003F82; suivant : 003F84Anti-RNA virus activity of polyoxometalates.
Auteurs : Shiro Shigeta [Japon] ; Shuichi Mori ; Toshihiro Yamase ; Norio Yamamoto ; Naoki YamamotoSource :
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [ 0753-3322 ] ; 2006.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Composés du tungstène (pharmacologie), Composés du tungstène (usage thérapeutique), Composés du vanadium (usage thérapeutique), Coronavirus (), Grippe humaine (traitement médicamenteux), Humains, Maladies virales (traitement médicamenteux), Orthomyxoviridae (), Ribavirine (pharmacologie), Ribavirine (usage thérapeutique), Résistance virale aux médicaments, Synergie des médicaments, Titane (usage thérapeutique), Virus à ARN ().
- MESH :
- pharmacologie : Antiviraux, Composés du tungstène, Ribavirine.
- traitement médicamenteux : Grippe humaine, Maladies virales.
- usage thérapeutique : Antiviraux, Composés du tungstène, Composés du vanadium, Ribavirine, Titane.
- Animaux, Coronavirus, Humains, Orthomyxoviridae, Résistance virale aux médicaments, Synergie des médicaments, Virus à ARN.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Coronavirus (drug effects), Drug Resistance, Viral, Drug Synergism, Humans, Influenza, Human (drug therapy), Orthomyxoviridae (drug effects), RNA Viruses (drug effects), Ribavirin (pharmacology), Ribavirin (therapeutic use), Titanium (therapeutic use), Tungsten Compounds (pharmacology), Tungsten Compounds (therapeutic use), Vanadium Compounds (therapeutic use), Virus Diseases (drug therapy).
- MESH :
- chemical , pharmacology : Antiviral Agents, Ribavirin, Tungsten Compounds.
- chemical , therapeutic use : Antiviral Agents, Ribavirin, Titanium, Tungsten Compounds, Vanadium Compounds.
- drug effects : Coronavirus, Orthomyxoviridae, RNA Viruses.
- drug therapy : Influenza, Human, Virus Diseases.
- Animals, Drug Resistance, Viral, Drug Synergism, Humans.
Abstract
The anti-RNA virus activity of polyoxometalates (POM) is reviewed, with a special emphasis on the anti-respiratory virus activities. There are many causative agents of acute viral respiratory infections; and it is rather difficult to identify the relevant agent in a given case by rapid clinical means. During acute progress of infection before the definitive diagnosis is obtained physicians need to prescribe certain broad spectrum anti-viral drugs. A titanium containing polyoxotungstate, PM-523 exhibited potent anti-influenza virus (FluV) A and anti-respiratory syncytial virus (RSV) activities in vitro. Therapeutic effect of FluV A infected mice with aerosol inhalation of PM-523 was proven. A vanadium substituted polyoxotungstate, PM-1001 has antiviral activity against FluV A, RSV, parainfluenza virus (PfluV) type 2, Dengue fiver virus, HIV-1 and SARS coronavirus in vitro. Thus, POMs have been proven to be broad spectrum and non-toxic anti-RNA virus agents in both in vitro and in vivo experiments and are promising candidates for first-line therapeutics in acute respiratory diseases.
DOI: 10.1016/j.biopha.2006.03.009
PubMed: 16737794
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002221
- to stream PubMed, to step Curation: 002221
- to stream PubMed, to step Checkpoint: 002297
- to stream Ncbi, to step Merge: 001516
- to stream Ncbi, to step Curation: 001516
- to stream Ncbi, to step Checkpoint: 001516
- to stream Main, to step Merge: 004195
- to stream Main, to step Curation: 003F83
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-RNA virus activity of polyoxometalates.</title><author><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name><affiliation wicri:level="1"><nlm:affiliation>Bureau of Prefectural Hospitals, Fukushima Prefecture, Japan. sshigeta@fmu.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Bureau of Prefectural Hospitals, Fukushima Prefecture</wicri:regionArea><wicri:noRegion>Fukushima Prefecture</wicri:noRegion></affiliation></author><author><name sortKey="Mori, Shuichi" sort="Mori, Shuichi" uniqKey="Mori S" first="Shuichi" last="Mori">Shuichi Mori</name></author><author><name sortKey="Yamase, Toshihiro" sort="Yamase, Toshihiro" uniqKey="Yamase T" first="Toshihiro" last="Yamase">Toshihiro Yamase</name></author><author><name sortKey="Yamamoto, Norio" sort="Yamamoto, Norio" uniqKey="Yamamoto N" first="Norio" last="Yamamoto">Norio Yamamoto</name></author><author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16737794</idno><idno type="pmid">16737794</idno><idno type="doi">10.1016/j.biopha.2006.03.009</idno><idno type="wicri:Area/PubMed/Corpus">002221</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002221</idno><idno type="wicri:Area/PubMed/Curation">002221</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002221</idno><idno type="wicri:Area/PubMed/Checkpoint">002297</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002297</idno><idno type="wicri:Area/Ncbi/Merge">001516</idno><idno type="wicri:Area/Ncbi/Curation">001516</idno><idno type="wicri:Area/Ncbi/Checkpoint">001516</idno><idno type="wicri:doubleKey">0753-3322:2006:Shigeta S:anti:rna:virus</idno><idno type="wicri:Area/Main/Merge">004195</idno><idno type="wicri:Area/Main/Curation">003F83</idno><idno type="wicri:Area/Main/Exploration">003F83</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-RNA virus activity of polyoxometalates.</title><author><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name><affiliation wicri:level="1"><nlm:affiliation>Bureau of Prefectural Hospitals, Fukushima Prefecture, Japan. sshigeta@fmu.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Bureau of Prefectural Hospitals, Fukushima Prefecture</wicri:regionArea><wicri:noRegion>Fukushima Prefecture</wicri:noRegion></affiliation></author><author><name sortKey="Mori, Shuichi" sort="Mori, Shuichi" uniqKey="Mori S" first="Shuichi" last="Mori">Shuichi Mori</name></author><author><name sortKey="Yamase, Toshihiro" sort="Yamase, Toshihiro" uniqKey="Yamase T" first="Toshihiro" last="Yamase">Toshihiro Yamase</name></author><author><name sortKey="Yamamoto, Norio" sort="Yamamoto, Norio" uniqKey="Yamamoto N" first="Norio" last="Yamamoto">Norio Yamamoto</name></author><author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name></author></analytic><series><title level="j">Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</title><idno type="ISSN">0753-3322</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus (drug effects)</term><term>Drug Resistance, Viral</term><term>Drug Synergism</term><term>Humans</term><term>Influenza, Human (drug therapy)</term><term>Orthomyxoviridae (drug effects)</term><term>RNA Viruses (drug effects)</term><term>Ribavirin (pharmacology)</term><term>Ribavirin (therapeutic use)</term><term>Titanium (therapeutic use)</term><term>Tungsten Compounds (pharmacology)</term><term>Tungsten Compounds (therapeutic use)</term><term>Vanadium Compounds (therapeutic use)</term><term>Virus Diseases (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Composés du tungstène (pharmacologie)</term><term>Composés du tungstène (usage thérapeutique)</term><term>Composés du vanadium (usage thérapeutique)</term><term>Coronavirus ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Humains</term><term>Maladies virales (traitement médicamenteux)</term><term>Orthomyxoviridae ()</term><term>Ribavirine (pharmacologie)</term><term>Ribavirine (usage thérapeutique)</term><term>Résistance virale aux médicaments</term><term>Synergie des médicaments</term><term>Titane (usage thérapeutique)</term><term>Virus à ARN ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Ribavirin</term><term>Tungsten Compounds</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Ribavirin</term><term>Titanium</term><term>Tungsten Compounds</term><term>Vanadium Compounds</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term><term>Orthomyxoviridae</term><term>RNA Viruses</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Composés du tungstène</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Composés du tungstène</term><term>Composés du vanadium</term><term>Ribavirine</term><term>Titane</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Resistance, Viral</term><term>Drug Synergism</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Coronavirus</term><term>Humains</term><term>Orthomyxoviridae</term><term>Résistance virale aux médicaments</term><term>Synergie des médicaments</term><term>Virus à ARN</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The anti-RNA virus activity of polyoxometalates (POM) is reviewed, with a special emphasis on the anti-respiratory virus activities. There are many causative agents of acute viral respiratory infections; and it is rather difficult to identify the relevant agent in a given case by rapid clinical means. During acute progress of infection before the definitive diagnosis is obtained physicians need to prescribe certain broad spectrum anti-viral drugs. A titanium containing polyoxotungstate, PM-523 exhibited potent anti-influenza virus (FluV) A and anti-respiratory syncytial virus (RSV) activities in vitro. Therapeutic effect of FluV A infected mice with aerosol inhalation of PM-523 was proven. A vanadium substituted polyoxotungstate, PM-1001 has antiviral activity against FluV A, RSV, parainfluenza virus (PfluV) type 2, Dengue fiver virus, HIV-1 and SARS coronavirus in vitro. Thus, POMs have been proven to be broad spectrum and non-toxic anti-RNA virus agents in both in vitro and in vivo experiments and are promising candidates for first-line therapeutics in acute respiratory diseases.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Mori, Shuichi" sort="Mori, Shuichi" uniqKey="Mori S" first="Shuichi" last="Mori">Shuichi Mori</name><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name><name sortKey="Yamamoto, Norio" sort="Yamamoto, Norio" uniqKey="Yamamoto N" first="Norio" last="Yamamoto">Norio Yamamoto</name><name sortKey="Yamase, Toshihiro" sort="Yamase, Toshihiro" uniqKey="Yamase T" first="Toshihiro" last="Yamase">Toshihiro Yamase</name></noCountry><country name="Japon"><noRegion><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003F83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16737794
|texte= Anti-RNA virus activity of polyoxometalates.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16737794" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |